Skip to content
Richard-Devine

Richard-Devine

Food 100% guaranteed

Primary Menu
  • food restaurants
  • Food & Cooking
  • Technology
  • Real Estate
  • health
  • Sports
  • About Us
    • Advertise Here
    • Contact Us
    • Privacy Policy
    • Sitemap
  • Home
  • New Data in Simultaneous Pancreas-Kidney Transplantation Further Demonstrates the Value of Prospera dd-cfDNA Technology
  • Technology

New Data in Simultaneous Pancreas-Kidney Transplantation Further Demonstrates the Value of Prospera dd-cfDNA Technology

By Damaris J. Dickerson 1 year ago

[ad_1]

Biopsy-matched study assesses pancreas rejection in the context of a simultaneous kidney-pancreas transplant

AUSTIN, Texas, March 22, 2022 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a study1 reporting on the performance of donor-derived cell-free DNA (dd-cfDNA) testing using the Prospera™ technology for the assessment of pancreas graft rejection in simultaneous pancreas-kidney (SPK) transplantation has been published in Transplantation, the official Journal of The Transplantation Society.

(PRNewsfoto/Natera, Inc.)

(PRNewsfoto/Natera, Inc.)

The study, conducted at the Hospital Clinic of Barcelona, Spain, utilized Prospera technology to detect rejection of a pancreas graft in 36 SPK transplant recipients with pancreas biopsy-matched plasma samples. Pancreas graft status in SPK transplants is currently assessed by non-specific biochemical markers, typically amylase and/or lipase, and confirmed by biopsy.

As shown in the study results, the combination of dd-cfDNA donor fraction and quantity reported using Prospera technology outperformed both current biochemical markers and dd-cfDNA donor fraction-alone in assessing pancreas rejection. Dd-cfDNA quantity alone also demonstrated exceptional performance, detecting rejection with a sensitivity of 85.7% and a specificity of 93.7% and achieving an AUC of 0.89 compared to 0.74 for lipase and 0.46 for amylase.

“Our study clearly indicates that the use of routine dd-cfDNA testing can help clinicians better monitor and manage treatment options, particularly over the current tests which are highly unspecific,” said Pedro Ventura-Aguiar, M.D., Ph.D., the study’s author and principal investigator. “This data also cements the importance of incorporating dd-cfDNA quantity and not just looking at donor-fraction alone. It’s great that Natera can enable this type of analysis with Prospera.”

“We’ve previously validated the Prospera test for use in the clinical management of simultaneous pancreas-kidney transplant patients to detect kidney rejection,” said Bernie Tobin, general manager, organ health at Natera. “New advances may enable the ability to detect pancreatic rejection as well. SPK transplant recipients face a complex array of challenges and we’re pleased to be on the leading edge of research and striving to improve care for these patients.”

About the Prospera test

The Prospera test leverages Natera’s core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction and quantity of donor-derived cell-free DNA (dd-cfDNA) in the recipient’s blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy. The Prospera test has been clinically and analytically validated for performance regardless of donor relatedness, rejection type, and clinical presentation. It has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical or other studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350
Media: Kate Stabrawa, Communications, Natera, Inc., 720-318-4080 [email protected]

References

  1. Ventura-Aguiar P, Ramirez-Bajo MJ, Rovira J, et al. Donor-derived Cell-free DNA Shows High Sensitivity for the Diagnosis of Pancreas Graft Rejection in Simultaneous Pancreas-Kidney Transplantation. Transplantation. 2022. DOI: 10.1097/TP.0000000000004088.

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-data-in-simultaneous-pancreas-kidney-transplantation-further-demonstrates-the-value-of-prospera-dd-cfdna-technology-301507267.html

SOURCE Natera, Inc.

[ad_2]

Source link

Tags: Food Near Me Now, Food Near Us, Food Network Recipes, Food Open, Food Open Late, Food Open Late Near Me, Food Open Near Me Now, Food Open Now, Food Open Right Now, Food Options, Food Pantry Near Me, Food Places, Food Places Near Me, Food Places Open Near Me, Food Preservative, Food Processor, Food Pyramid, Food Quality, Food Questions, Food Quincy, Food Quiz, Food Quotes, M Food Items, M Food Logo, M Food Mart Reno, N Food Court, N Food Items, N Food Mart, N Food Name, N Food Stamps, N Food Words, N Foods, N Foods For Thanksgiving, O Food Dumpling, O Food Gochujang, O Food List, O Food Truck, O Food Tteokbokki, O Foods, O Foods Ltd, O Foods Names, P Food Stamps, P Food Stamps 2022, P Foods, P Foods For Babies, P Foods For Constipation, P Foods For Constipation Baby, P Foods Names, P Foods To Help Constipation

Continue Reading

Previous Why Link-Worthy Content Wins and How to Make Most of It
Next 7 tricks for expert searches
June 2023
M T W T F S S
 1234
567891011
12131415161718
19202122232425
2627282930  
« May    

Archives

  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • March 2020
  • April 2019

Recent Posts

  • Vegetarian Shepherd’s Pie Recipe – Pinch of Yum
  • Bacon Wrapped Brussels Sprouts – Carlsbad Cravings
  • Italian Meatball Soup – Damn Delicious
  • Ham, Egg and Chive Waffles
  • Chicken meatballs with Gochujang and sesame

BL

Intellifluence Trusted Blogger

Tags

Food Near Me Now Food Near Us Food Network Recipes Food Open Food Open Late Food Open Late Near Me Food Open Near Me Now Food Open Now Food Open Right Now Food Options Food Pantry Near Me Food Places Food Places Near Me Food Places Open Near Me Food Preservative Food Processor Food Pyramid Food Quality Food Questions Food Quincy Food Quiz Food Quotes M Food Items M Food Logo M Food Mart Reno N Food Court N Food Items N Food Mart N Food Name N Foods N Foods For Thanksgiving N Food Stamps N Food Words O Food Dumpling O Food Gochujang O Food List O Foods O Foods Ltd O Foods Names O Food Truck O Food Tteokbokki P Foods P Foods For Babies P Food Stamps P Food Stamps 2022

getlinko

richard-devine.com | Magazine 7 by AF themes.

WhatsApp us